Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Palbociclib (PD 0332991) dihydrochloride is an orally active, selective inhibitor of CDK4 (IC50: 11 nM) and CDK6 (IC50: 16 nM). Palbociclib dihydrochloride has anti-proliferative activity and cell cycle arrest in HR-positive and HER2-negative breast cancers, as well as in hepatocellular carcinoma studies.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,520.00 | |
50 mg | 10-14 weeks | $ 1,980.00 | |
100 mg | 10-14 weeks | $ 2,500.00 |
Description | Palbociclib (PD 0332991) dihydrochloride is an orally active, selective inhibitor of CDK4 (IC50: 11 nM) and CDK6 (IC50: 16 nM). Palbociclib dihydrochloride has anti-proliferative activity and cell cycle arrest in HR-positive and HER2-negative breast cancers, as well as in hepatocellular carcinoma studies. |
Molecular Weight | 520.45 |
Formula | C24H31Cl2N7O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Palbociclib dihydrochloride inhibitor inhibit